Stephen Mock1, David J Osborn2, Elizabeth T Brown1, W Stuart Reynolds1, Maxim Turchan3, Srivatsan Pallavaram4, William Rodriguez4, Roger Dmochowski1, Christopher M Tolleson5. 1. Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA. 2. Department of Urology, Walter Reed National Military Medical Center, Bethesda, MD, USA. 3. Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA. 4. Department of Electrical Engineering and Computer Science, Vanderbilt University, Nashville, TN, USA. 5. Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA. christopher.tolleson@vanderbilt.edu.
Abstract
OBJECTIVE: Deep Brain Stimulation (DBS) is an established adjunctive surgical intervention for treating Parkinson's disease (PD) motor symptoms. Both surgical targets, the globus pallidus interna (GPi) and subthalamic nucleus (STN), appear equally beneficial when treating motor symptoms but effects on nonmotor symptoms are not clear. Lower urinary tract symptoms (LUTS) are a common PD complaint. Given prior data in STN-DBS, we aimed to further explore potential benefits in LUTS in both targets. METHODS: We performed a prospective, nonblinded clinical trial evaluating LUTS in PD patients in both targets pre and post DBS using validated urologic surveys. Participants were already slated for DBS and target selection predetermined before study entry. LUTS was evaluated using: the American Urological Association (AUA-SI), Quality of Life score (QOL), Overactive Bladder 8 Questionnaire (OAB-q), and Sexual Health Inventory for Men (SHIM). RESULTS: Of 33 participants, 20 underwent STN DBS and 13 had GPi DBS. Patients demonstrated moderate baseline LUTS. The urologic QOL score significantly improved post DBS (3.24 ± 1.77vs. 2.52 ± 1.30; p = 0.03). Analyzed by target, only the STN showed significant change in QOL (3.20 ± 1.61 vs 2.25 ± 1.33; p = 0.04). There were no other significant differences in urologic scores post DBS noted in either target. CONCLUSION: In PD patients with moderate LUTS, there were notable improvements in QOL for LUTS post DBS in the total sample and STN target. There may be differences in DBS effects on LUTS between targets but this will require further larger, blinded studies.
OBJECTIVE: Deep Brain Stimulation (DBS) is an established adjunctive surgical intervention for treating Parkinson's disease (PD) motor symptoms. Both surgical targets, the globus pallidus interna (GPi) and subthalamic nucleus (STN), appear equally beneficial when treating motor symptoms but effects on nonmotor symptoms are not clear. Lower urinary tract symptoms (LUTS) are a common PD complaint. Given prior data in STN-DBS, we aimed to further explore potential benefits in LUTS in both targets. METHODS: We performed a prospective, nonblinded clinical trial evaluating LUTS in PD patients in both targets pre and post DBS using validated urologic surveys. Participants were already slated for DBS and target selection predetermined before study entry. LUTS was evaluated using: the American Urological Association (AUA-SI), Quality of Life score (QOL), Overactive Bladder 8 Questionnaire (OAB-q), and Sexual Health Inventory for Men (SHIM). RESULTS: Of 33 participants, 20 underwent STN DBS and 13 had GPi DBS. Patients demonstrated moderate baseline LUTS. The urologic QOL score significantly improved post DBS (3.24 ± 1.77vs. 2.52 ± 1.30; p = 0.03). Analyzed by target, only the STN showed significant change in QOL (3.20 ± 1.61 vs 2.25 ± 1.33; p = 0.04). There were no other significant differences in urologic scores post DBS noted in either target. CONCLUSION: In PD patients with moderate LUTS, there were notable improvements in QOL for LUTS post DBS in the total sample and STN target. There may be differences in DBS effects on LUTS between targets but this will require further larger, blinded studies.
Authors: Enrico Finazzi-Agrò; Antonella Peppe; Andrea D'Amico; Filomena Petta; Paolo Mazzone; Paolo Stanzione; Francesco Micali; Carlo Caltagirone Journal: J Urol Date: 2003-04 Impact factor: 7.450
Authors: Christoph Seif; Jan Herzog; Christof van der Horst; Bettina Schrader; Jens Volkmann; Guenther Deuschl; Klaus-Peter Juenemann; Peter M Braun Journal: Ann Neurol Date: 2004-01 Impact factor: 10.422
Authors: M C Rodriguez-Oroz; J A Obeso; A E Lang; J-L Houeto; P Pollak; S Rehncrona; J Kulisevsky; A Albanese; J Volkmann; M I Hariz; N P Quinn; J D Speelman; J Guridi; I Zamarbide; A Gironell; J Molet; B Pascual-Sedano; B Pidoux; A M Bonnet; Y Agid; J Xie; A-L Benabid; A M Lozano; J Saint-Cyr; L Romito; M F Contarino; M Scerrati; V Fraix; N Van Blercom Journal: Brain Date: 2005-06-23 Impact factor: 13.501
Authors: Kenneth A Follett; Frances M Weaver; Matthew Stern; Kwan Hur; Crystal L Harris; Ping Luo; William J Marks; Johannes Rothlind; Oren Sagher; Claudia Moy; Rajesh Pahwa; Kim Burchiel; Penelope Hogarth; Eugene C Lai; John E Duda; Kathryn Holloway; Ali Samii; Stacy Horn; Jeff M Bronstein; Gatana Stoner; Philip A Starr; Richard Simpson; Gordon Baltuch; Antonio De Salles; Grant D Huang; Domenic J Reda Journal: N Engl J Med Date: 2010-06-03 Impact factor: 91.245
Authors: Tatiana Witjas; E Kaphan; J P Azulay; O Blin; M Ceccaldi; J Pouget; M Poncet; A Ali Chérif Journal: Neurology Date: 2002-08-13 Impact factor: 9.910
Authors: Pierre-François D'Haese; Srivatsan Pallavaram; Chris Kao; Joseph S Neimat; Peter E Konrad; Benoit M Dawant Journal: Stereotact Funct Neurosurg Date: 2013-02-27 Impact factor: 1.875
Authors: Anne Pavy-Le Traon; Nikki Cotterill; Gerard Amarenco; Susanne Duerr; Horacio Kaufmann; Heinz Lahrmann; François Tison; Gregor K Wenning; Christopher G Goetz; Werner Poewe; Cristina Sampaio; Anette Schrag; Olivier Rascol; Pablo Martinez-Martin; Glenn T Stebbins Journal: Mov Disord Clin Pract Date: 2018-10-25